Qvt Financial LP Adaptimmune Therapeutics PLC Transaction History

Qvt Financial LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$3.76 - $14.16 $1.4 Million - $5.26 Million	-371,617 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$10.42 - $13.74 $3.75 Million - $4.94 Million	-359,893 Reduced 49.2%	371,617 $4.26 Million
Q1 2018 May 15, 2018	SELL	$7.1 - $11.56 $868,862 - $1.41 Million	-122,375 Reduced 14.33%	731,510 $7.84 Million
Q4 2017 Feb 14, 2018	SELL	$6.68 - $8.74 $36,786 - $48,131	-5,507 Reduced 0.64%	853,885 $5.48 Million
Q3 2017 Nov 14, 2017	BUY	$4.93 - $8.93 $4.24 Million - $7.67 Million	859,392	859,392 $6.65 Million

123M

34.2K

16.3K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $47.4M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Qvt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Qvt Financial LP with notifications on news.